28 September 2023
ECO Animal Health Group plc
(''ECO", the "Company" or the "ECO Group")
(AIM: EAH)
ESG Rating
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it has achieved an A-rating for its ESG activities from Integrum ESG, who provide independent ESG ratings to a large number of companies.
An 'A' rating is the highest score possible and higher than approximately 300 other companies ranked in the same sub-sector. The rating reflects the ECO ESG strategy and activities and metrics, which are focused especially on environmental and social, particularly ethnic and gender diversity, aspects.
David Hallas, CEO commented: "ECO is committed to embedding sustainability into the high standards set for its business dealings. We recognise the value of incorporating the principles of Environment, Social and Governance (ESG) into everything we do and aspire to contribute to six of the UN SDGs which are aligned with our current and future business and intentions."
For further information please contact:
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher |
020 7496 3000 |
Investec (Joint Broker) Gary Clarence Lydia Zychowska Carlo Spingardi |
020 7597 5970
|
Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.